Science & Research

Researchers at the University of Mississippi have been awarded $1.37 million to study if cannabis can help manage HIV-related pain in patients.

The biotech pharma firm ANANDA Scientific Inc. announced it has received FDA approval to study a CBD-based drug as a treatment for opioid-use disorder.

Groff North America Hemplex and BRC, two cannabis cultivation firms, have harvested federally sanctioned cannabis for research purposes, ending a 50-year monopoly by the University of Mississippi.

A recent study found significant improvement in autism symptoms following treatment with THC-rich cannabis oil.

A recent study found that cannabis decriminalization policies have helped to reduce the racial disparity in cannabis possession arrests.

A set of GOP companion bills in the House and Senate seeking to curb illegal fentanyl sales would also streamline the research of cannabis, psychedelics, and other Schedule I substances.

Researchers at the University of Sydney in Australia have found that blood and oral fluid THC concentrations are weak indicators of cannabis-induced impairment.

A new study found that psilocybin may be able to reverse alcohol brain damage, reduce alcohol-addictive behavior, and reduce relapse rates.

NORML released an updated and revised version of “Clinical Applications for Cannabis & Cannabinoids: A Review of the Recent Scientific Literature, 2000-2021.” Proceeds from the book will be used to fund NORML’s advocacy efforts.

A recent survey found 65% of patients were able to reduce or eliminate taking at least one prescription medication after obtaining their medical cannabis registration.

Baltimore’s Johns Hopkins Medicine announced that the National Institutes of Health will provide nearly $4 million to help researchers study how psilocybin can affect tobacco addiction.

Bank of America suddenly canceled the account of cannabis research firm Scottsdale Research Institute despite being fully compliant with federal laws and operating with public DEA approval.

The DEA has proposed massively increasing the production of research-grade cannabis and psychedelics like LSD, psilocybin, and MDMA next year.

Researchers found that less than 2% of people living in states that have legalized cannabis have been diagnosed with “cannabis use disorder” and that the reforms were not linked to increased cannabis consumption among youths aged 12-20.

A recent survey found that 60% of cannabis consumers said they would consume cannabis with their grandparents.

Researchers found that withdrawal effects from synthetic cannabinoids appear more rapidly with consumers reporting more severe symptoms of insomnia, irritation and bad mood, heart palpitations, and loss of appetite.

Cannabis use among college students reached its highest levels in 35 years in 2020, according to the National Institute on Drug Abuse, while alcohol use decreased by 6%.

The DEA last week called for a significant increase in the production of cannabis and psilocybin for the purposes of federal research and clinical trials.

Cannabis use among cancer patients is lower than that of the general public, with just 9% of cancer patients having used cannabis compared to 14% of people with no cancer history according to a new study.

Included in the $1.2 trillion infrastructure bill passed by the Senate on Tuesday are provisions that would let researchers study cannabis from state-licensed dispensaries instead of the low-grade cannabis grown at government facilities.

According to a new study, 15% of remote employees worked from home under the influence of cannabis with the majority reporting benefits like decreased stress and increased creativity.

Pennsylvania-based research firm Affinity Bio Partners is investigating the potential efficacy of cannabis for diabetic nerve pain.

The United Kingdom National Health Service and Brain Tumour Charity are partnering on research to determine whether cannabis-based medicine Sativex paired with chemotherapy medication temozolomide can treat glioblastoma.

HIV-positive patients who consume cannabis daily have lower levels of neuroinflammation than non-cannabis consuming HIV-positive patients, according to a study.